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Abstract

Background: Buprenorphine, an underutilized pharmacotherapy, can play a key role in closing
the substantial opioid use disorder (OUD) treatment gap in the United States. Although 2016 US
legislation authorized trained nurse practitioners (NPs) to obtain the Drug Enforcement Agency
waiver to prescribe buprenorphine for OUD, many NPs do not have the waiver, and a large
proportion of waivered NPs do not prescribe to capacity. Purpose: To identify the therapeutic
commitment of Maine NPs to OUD as well as understand why Maine NPs do not adopt and
utilize buprenorphine for the treatment of OUD. Review of Evidence: Commitment to OUD and
adoption of buprenorphine in clinical practice is influenced by factors such as professional
support and education. Few studies have examined NP commitment to OUD and adoption of
buprenorphine. Project Design: A cross-sectional, Web-based survey measured the therapeutic
commitment of Maine NPs to OUD with the Drug and Drug Problems Perceptions
Questionnaire. Resources were identified that would encourage those without the buprenorphine
waiver to obtain it and those with the waiver to accept more patients. Methods: The online
survey was delivered to a convenience sample of NPs in Maine (N=299) in fall 2018. Results:
Maine NPs have a moderately high degree of overall therapeutic commitment to OUD. Maine
NPs in rural (p=.018) and urban (p=.024) practice settings and those with the buprenorphine
waiver (p<.001) had significantly higher overall therapeutic commitment scores than their
suburban and non-waivered NP counterparts. Professional support and education were priority
resources to increase buprenorphine adoption and utilization. Conclusion: To facilitate NP
commitment to OUD as well as NP adoption and utilization of buprenorphine, a comprehensive
approach with special emphasis on professional support and education is warranted.
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Introduction and Background
The United States (US) is in the midst of a devastating epidemic of fatal opioid
overdoses. Provisional data from 2017 reveal that nearly 50,000 US overdose deaths involved
opioid analgesics (e.g., morphine, oxycodone), along with heroin and illicit synthetic opioids
(e.g., fentanyl, carfentanil), yielding a four-fold increase in the total number of US opioid
overdose deaths since the turn of the 21st century (National Institute on Drug Abuse [NIDA],
2018). Consequently, on average, 130 Americans die every day from opioid overdoses (Centers
for Disease Control and Prevention [CDC], 2018). Opioid overdose fatalities are closely linked
with the rising rates of opioid use disorders (OUDs) (Soyka, 2015). At least 3 million people in
the US meet the diagnostic criteria for an OUD (US Office of the Surgeon General, 2016), which
is defined as a problematic pattern of opioid use causing significant impairment and failure to
meet major responsibilities at home, work, or school (American Psychiatric Association, 2013).
Untreated OUD increases the risk of early death, typically from overdose, trauma, suicide, or
infectious disease transmission, by a factor of 20 (Evans et al., 2015; Schuckit, 2016; Schwartz et
al., 2013; Teesson et al., 2015).
Despite the severity of the opioid epidemic, only 10% of the three-million Americans
who meet diagnostic criteria for an OUD are receiving evidence-based medication assisted
treatments (MATs) (US Office of the Surgeon General, 2016). Medication assisted treatment,
which combines the use of medication (e.g., buprenorphine, methadone, naltrexone) with
counseling and behavioral therapies, is the current standard of care for OUD and is endorsed by
the World Health Organization (WHO) as an International Standard for the Treatment of Drug
Use Disorders (Gerra, Koutsenok, Saenz, & Busse, 2015). Buprenorphine, one of the three
medications used as part of MAT, has high potential to address the persistent OUD treatment
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gap. Due to several of its favorable pharmacokinetic features (e.g., low side effect profile,
limited abuse potential, ease of management), buprenorphine is currently approved for use in US
primary care settings. Primary care-based buprenorphine demonstrated effectiveness at reducing
the risk of opioid overdose, improving social functioning, and decreasing infectious disease rates
(Kresina, Melinda, Lee, Ahadpour, & Robert, 2015; Mattick, Breen, Kimber, & Davoli, 2014;
Schwartz et al., 2013).
Primary care-based buprenorphine is now a well-established (Gerra et al., 2015),
evidence-based (Mattick et al., 2014; Schuckit, 2016), and cost-effective (Schackman, Leff,
Polsky, Moore, & Fiellin, 2012) treatment approach for OUD. However, access to this lifesaving treatment can be challenging. Historically, many of the barriers to accessing
buprenorphine for OUD were related to the workforce. Workforce barriers include shortages of
physicians, insufficient training, education, and experience, lack of peer and organizational
support, stigma, and inadequate reimbursement (Haffajee, Bohnert, & Lagisetty, 2018). The
Drug Addiction Treatment Act of 2000 (DATA 2000) was the first enacted US law of the 21st
century that aimed to overcome several workforce barriers; therefore, improving MAT access for
Americans by 1) increasing the pool of qualified physicians who could prescribe buprenorphine
for OUD; and 2) recognizing buprenorphine as a standard of care in primary care settings
(Thomas et al., 2017). Under DATA 2000, any physician who completes eight hours of training
is eligible to obtain a Drug Enforcement Administration (DEA) waiver to prescribe
buprenorphine for OUD (Thomas et al., 2017).
Although the pool of physicians with a DEA waiver has tripled since the enactment of
DATA 2000 (Stein et al., 2015), Substance Abuse and Mental Health Resource Administration
(SAMHSA, 2019) data indicate that less than 4% of all licensed US physicians are approved to

SCHOLARLY PROJECT REPORT

8

prescribe buprenorphine for OUD (Haffajee et al., 2018). Potential capacity for prescribing
buprenorphine has increased nationwide, but the treatment gap has not significantly narrowed
due to the rising numbers of Americans with OUDs (Jones, Campopiano, Baldwin, & McCanceKatz, 2015). Passage of the Comprehensive Addiction and Recovery Act of 2016 (CARA 2016)
represented an important legislative step by US lawmakers towards improving MAT access by
authorizing nurse practitioners (NPs) and physician assistants (PAs) to obtain the DEA waiver to
prescribe buprenorphine for OUD after completing 24 hours of training (US Congress, 2016).
Additional legislation passed in 2018 made this allowance permanent (US Congress, 2017).
Representing a large portion of the healthcare workforce, NPs and PAs are projected to make
significant contributions to buprenorphine treatment access (Andrilla, Patterson, Moore,
Coulthard, & Larson, 2018b).
Problem Statement
Although the incorporation of trained NPs and PAs into the primary care MAT workforce
has modestly increased the provider supply, the majority of NPs and PAs have not obtained the
DEA waiver to prescribe evidence-based buprenorphine for OUD (Andrilla, Moore, Patterson, &
Larson, 2018a). Further, of the small percentage of NPs and PAs who have obtained the DEA
waiver to prescribe buprenorphine for OUD, many are not prescribing buprenorphine to full
treatment capacity (Sigmon, 2015). Developing strategies to increase the pool of NPs and PAs
who both receive the DEA waiver to prescribe buprenorphine and prescribe to full treatment
capacity are critical to helping combat the opioid overdose epidemic and the rising rates of
OUDs. However, actionable approaches to address workforce barriers to adopting and
prescribing buprenorphine for OUD among NPs and PAs are lacking. If NPs and PAs face
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similar challenges as reported by physicians, the impact of their potential contributions under
CARA 2016 could be greatly diminished.
Purpose
The focus of the scholarly project is the therapeutic response of Maine NPs to the rising
rates of OUDs nationwide. First, the scholarly project sought to identify the overall therapeutic
commitment of Maine NPs in relation to caring for individuals with OUD. This included
exploring the various attitudinal components that comprise role security (e.g., role adequacy,
legitimacy, and support) and therapeutic commitment (e.g., role satisfaction and self-esteem)
(Shaw, Cartwright, Spratley, & Harwin, 1978). Second, the scholarly project sought to
characterize reasons that Maine NPs may not be waivered to prescribe buprenorphine for OUD
and reasons for not prescribing to full treatment capacity among waivered Maine NPs. The goals
of the scholarly project were to provide insight to the advanced practice registered nursing
(APRN) community in Maine regarding actionable approaches that might raise NP therapeutic
commitment to patient care involving OUD as well as augment adoption and prescribing of
buprenorphine for OUD.
Research Questions
In alignment with the overarching aim of exploring the therapeutic response of Maine
NPs in relation to caring for individuals with OUD, the scholarly project was designed to answer
three fundamental questions:
1. How therapeutically committed are Maine NPs in relation to caring for patients with
OUD?
2. Is buprenorphine waiver status (waivered or not waivered) associated with overall
therapeutic commitment scores among Maine NPs?
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3. Is practice setting (urban, suburban, or rural) associated with overall therapeutic
commitment scores among Maine NPs?
Hypotheses
In alignment with the research questions outlined above, the scholarly project tested three
hypotheses:
1. Collectively, Maine NPs will report an overall therapeutic commitment score greater than
100, demonstrating positive attitudes towards caring for individuals with OUD.
2. Maine NPs who have obtained the buprenorphine waiver will report higher overall
therapeutic commitment scores than their non-waivered NP counterparts.
3. Maine NPs in rural practices settings will report higher overall therapeutic commitment
scores than their NP counterparts in suburban and urban practice settings.
Rationale
Given the nationwide focus on the opioid epidemic, the project leader predicted that
Maine NPs as a collective group will report moderately high scores of overall therapeutic
commitment (>100) to individuals with OUD. The project leader also predicted that Maine NPs
with the DEA waiver to prescribe buprenorphine for OUD will report higher overall therapeutic
commitment scores than their non-waivered NP counterparts. Additional training and
professional support—vital to the path of becoming a waivered healthcare provider—are
important factors that raise therapeutic commitment (Brooklyn & Sigmon, 2017; Sigmon, 2015).
Lastly, since NPs are increasingly present in rural settings (Barnes, Richards, McHugh, &
Martsolf, 2018) and the opioid epidemic is of particular concern in rural Maine where many
residents encounter multiple socioeconomic vulnerabilities that negatively impact their ability to
access care (Keyes, Cerdá, Brady, Havens, & Galea, 2014; Lenardson, Gale, & Ziller, 2016), the
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project leader predicted that NPs in rural settings will report higher overall therapeutic
commitment scores than their NP counterparts in urban and suburban settings.
Review of Evidence
Leveraging the NP Workforce
Until passage of CARA 2016, NPs have been an untapped resource that could be used to
help alleviate the shortage of healthcare providers authorized and willing to prescribe
buprenorphine for OUD. With more than 248,000 NPs licensed in the US, 86.6% are certified in
an area of primary care (American Association of Nurse Practitioners [AANP], 2018). The CDC
and WHO advocate for the expansion of buprenorphine into primary care for several reasons
(Dowell, Haegerich, & Chou, 2016; Gerra et al., 2015). Patients with OUD tend to prefer
primary care-based buprenorphine because it is often a holistic setting that offers more
personalized and integrated care and the unique opportunity to develop a long-term relationship
with their provider of choice (Barry et al., 2009; Fox, Masyukova, & Cunningham, 2016;
Haffajee et al., 2018). Patients with OUD also report that primary care-based buprenorphine
mitigates the stigma and shame of being seen at a specialty clinic (Rawson, Rieckmann, & Gust,
2014). With the profession’s reputation as part of the most trusted and ethical profession
nationwide for over a decade, coupled by their double-digit growth and one-billion patient visits
annually, NPs are positioned as an essential component to the expansion of access to evidencebased buprenorphine for OUD in US primary care settings (AANP, n.d.). Since NPs in primary
care provide high-quality, patient-centered care and have patient outcomes and satisfaction
scores comparable to physician colleagues (Stanik-Hutt et al., 2013), leveraging the pool of
trained NPs to prescribe buprenorphine can have a major impact in terms of improving treatment
access, quality, and capacity.
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Contributions of the NP Early Adopters
Since CARA 2016 was enacted, approximately 6,000 (2.4%) NPs have obtained the DEA
waiver and become early adopters of buprenorphine treatment in their practices, which in turn
created critical access points to more than 180,000 patients nationwide (Knestrick, 2018). The
inclusion of NPs as prescribers of buprenorphine for OUD adds tremendous value for rural
communities where one in four medical providers is a NP (Barnes et al., 2018). More than half of
rural counties in the US lack a physician with a buprenorphine waiver (Andrilla et al., 2018a).
Primary care-based buprenorphine delivered by trained NPs provides an effective alternative to
receiving care in specialized treatment centers, which are often unavailable in most rural areas,
have prolonged waiting periods, and require patients to drive long distances (Sigmon, 2015).
Allowing NPs to obtain the DEA waiver and prescribe buprenorphine for OUD increases the
overall number of rural patients potentially treated by 10,777, according to a recent projection
(Andrilla et al., 2018b). Likewise, Wilson and Fagan (2017) demonstrated the addition of a
buprenorphine-certified NP increased the number of patients with OUD treated in rural North
Carolina. The evidence points to the urgent need for the development of innovative strategies to
increase NP adoption and prescribing of buprenorphine in primary care, and ultimately, ensure
timely and equitable MAT is available for individuals with OUD.
NP Workforce Barriers
The emerging role of trained NPs in buprenorphine treatment presents a unique set of
regulatory challenges for the profession related to practice authority. Although CARA 2016
addresses the differences in state NP practice environments, laws that prohibit full practice
authority can reduce buprenorphine access in almost half of the states in the nation (Fornili &
Fogger, 2017). In states where NPs have full practice authority, a greater percentage of NPs were

SCHOLARLY PROJECT REPORT

13

expected to obtain and use their DEA waiver to prescribe buprenorphine for OUD than had done
so by early 2018 (Andrilla et al., 2018b). Full practice authority states also saw larger actual and
relative projected increases in the estimated number of patients with OUD being treated with
buprenorphine (Andrilla et al., 2018b). Whereas physicians can prescribe buprenorphine for a
maximum 275 patients with OUD, NPs are limited to 30 patients during their first year of
prescribing and 100 thereafter (Andrilla et al., 2018b; Haffajee et al., 2018; Fornili & Fogger,
2017). Practice authority and patient limit barriers erode the potential contributions of NPs at a
time when it is critical to recruit and retain NPs with the DEA waiver to prescribe buprenorphine
in the healthcare workforce.
Facilitators of Effective Primary Care-Based Buprenorphine
The overarching aim of recent policy efforts by US lawmakers and public health leaders
is to raise the commitment of the primary care workforce to patient care involving OUD.
Commitment to OUD-related patient care is associated with increased professional motivation,
self-esteem, and satisfaction (Becker & Fiellin, 2006; Palmer, Murphy, Piselli, & Ball, 2009;
Shaw et al., 1978). However, the unique set of NP workforce barriers are a consequential threat
to the long-term commitment and therapeutic response of NPs. To improve professional
commitment to patient care involving OUD, the evidence suggests that 1) acknowledging a
professional responsibility to respond, 2) professional training and education, and 3) professional
support structures are necessary to recruit and retain buprenorphine-waivered prescribers, and to
reach full treatment capacity. The identified facilitators showcase strategies to enhance the
professional commitment of NPs in relation to the adoption and prescribing of buprenorphine for
patients with OUD.
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Professional Responsibility. Under CARA 2016, US lawmakers extended the
professional responsibility of treating patients with OUD to trained NPs in primary care settings.
The intentions of primary care-based buprenorphine are not only to improve MAT access, but
also to further the perspective that OUD is similar to other chronic medical conditions (e.g.,
diabetes and hypertension), thereby diminishing the social stigma often attached to this patient
population and long-term, evidence-based treatment (Rawson et al., 2014). Healthcare providers
who believe it is their professional responsibility to respond to OUD in an evidence-based
manner, similar to other diseases managed in their clinics, are more likely to execute an effective
therapeutic response (Barnett, Hall, Fry, Dilkes-Frayne, & Carter, 2017; Shaw et al., 1978).
Acknowledging a professional responsibility to respond to OUD with evidence-based
buprenorphine in primary care is correlated with less stigmatizing attitudes (Duncan et al., 2015),
and greater provider willingness to obtain and use the buprenorphine waiver to full treatment
capacity (Andrilla, Coulthard, & Larson, 2017; Hutchinson, Catlin, Andrilla, Baldwin, &
Rosenblatt, 2014). Organizations that promote a culture where responding to OUD is a
professional responsibility are also more likely to see an effective therapeutic response to OUD
in their frontline providers (Ober et al., 2017).
Professional Training and Education. Because primary care providers have largely
been untrained or undereducated to respond effectively to OUD, they often feel they have
nothing to offer the individual who presents with an OUD other than referral to a mental health
specialist. Extending the ability to prescribe buprenorphine to trained NPs counters the common
fallacy that they have nothing to offer patients with OUD in the primary care setting. Instead, the
authority of trained NPs to prescribe buprenorphine gives this large portion of the primary care
workforce an opportunity to furnish their patients with an effective, evidence-based MAT.
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Primary care providers who engage in the professional training and education required to obtain
the buprenorphine waiver improve their ability to detect OUD early and treat accordingly,
contributing to enhanced care and outcomes for patients (Aldridge, Linford, & Bray, 2017).
Additional training and education on OUD also facilitates provider confidence (Andrilla et al.,
2017; Hutchinson et al., 2014), extinguishes provider skepticism of buprenorphine’s
effectiveness (Hutchinson et al., 2014), accelerates provider practices consistent with national
guidelines (Quest, Merrill, Roll, Saxon, & Rosenblatt, 2012; Walley et al., 2008) as well as
improves overall provider satisfaction with this patient population (Becker & Fiellin, 2006;
Palmer et al., 2009).
Professional Support. Available professional support is vital for primary care providers,
including NPs, as newly eligible prescribers of buprenorphine. This includes support from
practice partners and organizational leadership as well as access to mental health specialists
(Andrilla et al., 2017; Hutchinson et al., 2014; Molfenter et al., 2015). Effective communication
and care coordination among the entire interdisciplinary team—primary care providers, practice
partners, mental health specialists, social workers, nurses, counselors, and organizational
leaders—boost the positive outcomes associated with primary care-based buprenorphine
(Andrilla et al., 2017; Hersh, Little, & Gleghorn, 2011). The Vermont Hub and Spoke treatment
model for individuals with OUD exemplifies ideal professional support, communication, and
care coordination among the interdisciplinary team (Brooklyn & Sigmon, 2017; Sigmon, 2015).
This innovative OUD treatment model, which creates specialized clinics (“hubs”) that provide
consultation and support to a network of primary care providers (“spokes”), is predictive of
obtaining the DEA waiver for buprenorphine and buprenorphine prescribing (Brooklyn &
Sigmon, 2017; Sigmon, 2015).
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The Theory of Therapeutic Commitment
Background
In London, England, during the mid-1970s, theorists Shaw and colleagues (1978)
observed a general reluctance among non-specialist healthcare providers (equivalent to the 21st
century US primary care provider) to work with the rising numbers of individuals with alcohol
use disorder (AUD), hypothesizing that moralistic attitudes and behaviors were the primary
contributors of this particular response. Since non-specialists felt like they had not received
formal education or support to care for individuals with AUD, they were uncertain as to whether
drinking problems came within their professional responsibilities. Consequently, many nonspecialists felt insecure in their role when responding to individuals with AUD, which
represented a considerable threat to their professional self-esteem. The non-specialist community
did not blame their working situation for their feelings of insecurity, but chose a simpler
rationalization of projecting their feelings of insecurity onto individuals with AUD,
characterizing them as unmotivated and worthless. To protect their professional self-esteem,
non-specialist providers safeguarded themselves by maintaining low commitment to individuals
with AUD (Shaw et al., 1978).
Informed by their observations, Shaw and colleagues (1978) proposed that the key to
leveraging the effectiveness of non-specialist providers was to provide education and training in
a supportive working environment to improve their role security and therapeutic commitment.
As their work progressed, Shaw and colleagues reconceptualized the question of how to improve
the response into how to raise the therapeutic commitment of non-specialist providers to care for
individuals with AUD. Shaw and colleagues firmly believed that improving the response to
drinking problems was not a matter of connecting individuals with AUD to more specialists, but
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rather focusing on broadening the base of the response to include non-specialist providers
working within the community. A comprehensive community response could not be achieved
without effective non-specialist providers. The non-specialist community, however, must be
assisted in a direction away from role insecurity and towards a supportive environment in which
they can attain the prime characteristics of clinical effectiveness—high therapeutic commitment
(Shaw et al., 1978).
Overview
The theory of therapeutic commitment is a two-stage process in which the non-specialist
healthcare provider first develops role security and then a sense of therapeutic commitment to
individuals with substance use disorders (SUDs) (Shaw et al., 1978; Watson, Maclaren, & Kerr,
2007). Without role security, the healthcare provider cannot reach or maintain a position of
therapeutic commitment to individuals with SUDs (Shaw et al., 1978; Watson, Maclaren, &
Kerr, 2007). Figure 1 illustrates the project leader’s visualization of Shaw and colleagues’ (1978)
theory of therapeutic commitment.
Stage 1: Role Security
Role security refers to the degree the healthcare provider feels secure about caring for
individuals with SUDs (Shaw et al., 1978; Watson, Maclaren, & Kerr, 2007). The subconcepts
that comprise role security include role adequacy, legitimacy, and support. Whereas role
adequacy refers to the provider’s knowledge base and skills in caring for patients with SUDs,
role legitimacy refers to the provider’s regard that care involving individuals with SUDs is his or
her professional responsibility. Role support refers to the extent the provider feels supported to
participate in care involving individuals with SUDs (Shaw et al., 1978; Watson, Maclaren, &
Kerr, 2007).
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Stage 2: Therapeutic Commitment
Therapeutic commitment refers to the degree the healthcare provider engages individuals
with SUDs and finds this work personally and professionally rewarding (Shaw et al., 1978;
Watson, Maclaren, & Kerr, 2007). The subconcepts that comprise therapeutic commitment
include role motivation, satisfaction, and self-esteem. Whereas role motivation refers to the
provider’s desire to work with patients who have SUDs, role satisfaction refers to the provider’s
fulfillment of professional expectations while working with patients with SUDs. Role self-esteem
refers to the provider’s confidence while delivering care for patients with SUDs (Shaw et al.,
1978; Watson, Maclaren, & Kerr, 2007).
The Relationship Between Role Security and Therapeutic Commitment
Strong role security is associated with high levels of therapeutic commitment (Anderson,
2006; Shaw et al., 1978; Watson, Maclaren, & Kerr, 2007). To illustrate this relationship, the
project leader created a new graphic visualizing role security as the key unlocking the healthcare
provider’s therapeutic commitment to individuals with SUDs in clinical practice (see Figure 1).
To be role secure, the provider must maintain a firm grip on the key’s bow, which represents role
adequacy, legitimacy, and support. The lock, which represents the healthcare provider’s
therapeutic commitment to patients with SUDs in clinical practice, can only be opened by the
key representing role security. The provider who maintains role security unlocks his or her
therapeutic commitment to patients with SUDs and displays role motivation, satisfaction, and
self-esteem (Shaw et al., 1978).
The Outcomes of a Role Secure and Therapeutically Committed Healthcare Provider
In relation to patient care involving SUDs, Shaw and colleagues (1978) posited that
strong role security and high levels of therapeutic commitment among non-specialist healthcare
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providers lead to improved clinical effectiveness, patient outcomes, and job satisfaction. Role
security extinguishes the provider’s role anxiety in relation to caring for individuals with SUDs,
and therefore, positively impacts the provider-patient relationship. Non-specialist healthcare
providers who are role secure and therapeutically committed will consistently and confidently
demonstrate professional characteristics while engaging in care that involves individuals with
SUDs, such as warmth and empathy, optimism about his or her clinical work, positive regard for
the patient as a person of value and worth in lieu of placing blame, therapeutic listening skills,
insight into the patient’s lived experience, and the provision of sound professional advice (see
Table 1) (Shaw et al., 1978).
Application
The general reluctance of non-specialist healthcare providers in London, England, during
the mid-1970s, towards the rising number of individuals with AUD parallels the sentiments of
many US primary care providers who are reluctant to engage in care involving patients with
OUDs (Huhn & Dunn, 2017), despite the rising numbers of individuals with OUDs nationwide
(Soyka, 2015). Although tapped by US policymakers to play a greater role in OUD treatment,
many primary care providers lack clarity about their role, feeling unprepared and unsupported
(Haffajee, Bohnert, & Lagisetty, 2018). Since NPs are increasingly filling critical gaps in
primary care as evidenced by the recent authorization of trained NPs to obtain and use the DEA
waiver to prescribe buprenorphine for OUD (US Congress, 2016), APRN leadership recognizes
the urgent need to develop the NP’s knowledge and skills related to the management of OUD in
a supportive clinical environment, enabling NPs to deliver high-quality, cost-effective care for
individuals with OUDs (Knestrick, 2018).
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Inspired by Shaw and colleagues’ (1978) theoretical framework, the aim of the scholarly
project was to identify and describe the role security and therapeutic commitment of NPs in
Maine in relation to caring for individuals with OUD. This aim was accomplished by measuring
the overall therapeutic commitment of Maine NPs with the refined Drug and Drug Problems
Perceptions Questionnaire (DDPPQ), which conforms to Shaw and colleagues’ (1978)
theoretical framework (Watson, Maclaren, & Kerr, 2007). For the purpose of the scholarly
project, measuring the role security and therapeutic commitment of Maine NPs with the DDPPQ
was an important first step to address factors that might raise the overall therapeutic commitment
of Maine NPs to OUD, including but not limited to the knowledge and skills related to delivering
quality care for individuals with OUD and the availability of professional support (Watson,
Maclaren, & Kerr, 2007).
Project Design
Overview
A cross-sectional, Web-based survey design was constructed to collect data measuring
the overall therapeutic commitment of Maine NPs to OUD as well as understand why NPs in
Maine do not adopt and utilize buprenorphine for the treatment of OUD. The survey was
delivered to a purposeful convenience sample of NPs licensed to practice in Maine known to the
project leader or referred by project team members between October 2018 and November 2018.
The survey was classified as exempt from human research by the Belmont University
Institutional Review Board. Participation was voluntary and all responses were kept confidential
and anonymous.
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Population
There are approximately 1,700 NPs licensed to practice in Maine with a mean age of 49
(Skillman, Stubbs, & Dahal, 2018). Maine NPs currently have full practice autonomy and
prescriptive authority (Nurse Practice Act, 32 M.R.S.A. § 2102; AANP, 2017). Shortly after the
federal passage of CARA 2016, Maine state lawmakers authorized trained NPs to obtain the
DEA waiver to prescribe buprenorphine for OUD. According to SAMHSA (2019) data, a total of
88 NPs in Maine are authorized to prescribe buprenorphine for OUD, meaning that 5% of NPs
licensed to practice in Maine have obtained the DEA waiver to prescribe buprenorphine for
OUD. To be eligible to participate in the survey for the scholarly project, respondents had to
report being a NP currently licensed to practice in Maine. Maine NPs (both those who do and do
not hold the buprenorphine waiver) were primarily recruited through the Maine Nurse
Practitioner Association (MNPA) list serve. The project leader also queried search engine results
and collegial referrals in order to compile email addresses. It was not possible to compute the
response rate as the project leader was unable to determine how many email invitations were
active or reached Maine NPs.
Survey Instrumentation
Overview. The finalized survey for the scholarly project was a combination of 1) the
refined 20-item DDPPQ (Watson, Maclaren, & Kerr, 2007); 2) five questions from a previous
study adapted to explore NP attitudes in Maine regarding buprenorphine adoption and
prescribing for OUD (Huhn & Dunn, 2017); and 3) demographic data (see Appendix A for the
finalized survey). The survey concluded with an invitation to enter the random drawing for a
$500 Visa gift card for participation. A pilot of the survey was sent to classmates, project team

SCHOLARLY PROJECT REPORT

22

members, and experts in the field of addiction medicine for face validity, clarity, and brevity
prior to the official launch.
The Refined DDPPQ. The finalized survey included the refined DDPPQ, a valid and
reliable 20-item tool (Cronbach’s alpha=0.87) used to measure the overall therapeutic
commitment of Maine NPs in relation to caring for patients with OUDs (Watson, Maclaren, &
Kerr, 2007). The refined DDPPQ contains five subscales—role adequacy, legitimacy, support,
satisfaction, and self-esteem (conforming to Shaw’s theory of therapeutic commitment). Items
related to role motivation (a subconcept in Shaw’s theory of therapeutic commitment) were
subsumed within the subscale of role self-esteem, implying that the provider who holds greater
confidence is more motivated and satisfied in his or her work involving patients with SUDs
(Watson, Maclaren, & Kerr, 2007). Mahmoud and colleagues (2017) confirmed the 20-item fivefactor DDPPQ structure. Likewise, the structure of the refined DDPPQ was retained, but the
wording changed such that ‘drug users’ was replaced by ‘patients with opioid use disorder,’ and
‘drugs’ by ‘opioids/opiates.’
Role security subscales in the DDPPQ (12 total items). The following descriptions of the
three role security subscales contained in the DDPPQ are provided:
1. Role adequacy subscale (7 items, Cronbach’s alpha = 0.94): This subscale was
modified to measure the extent to which NPs in Maine believe they have sufficient
knowledge of the causes and symptoms of OUD to enable them to carry out their
professional role in clinical practice (Shaw et al., 1978; Watson, Maclaren, & Kerr,
2007).
2. Role legitimacy subscale (2 items, Cronbach’s alpha = 0.80): This subscale was
modified to measure the extent to which NPs in Maine view particular aspects of OUD-
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related patient care as being their responsibility in clinical practice (Shaw et al., 1978;
Watson, Maclaren, & Kerr, 2007).
3. Role support subscale (3 items, Cronbach’s alpha = 0.78): This subscale was modified
to measure the extent to which NPs in Maine acknowledge receiving support from
colleagues to perform their role effectively for patients with OUD in clinical practice
(Shaw et al., 1978; Watson, Maclaren, & Kerr, 2007).
Therapeutic commitment subscales in the DDPPQ (8 total items). The following
descriptions of the two therapeutic commitment subscales are provided:
1. Role satisfaction subscale (4 items, Cronbach’s alpha = 0.89): This subscale was
modified to measure the extent to which NPs in Maine find professional satisfaction in
caring for patients with OUD (Shaw et al., 1978; Watson, Maclaren, & Kerr, 2007).
2. Role self-esteem subscale (4 items, Cronbach’s alpha = 0.69): This subscale was
modified to measure the extent to which NPs in Maine have confidence in their ability to
deliver care to patients with OUD (Shaw et al., 1978; Watson, Maclaren, & Kerr, 2007).
Scoring of the Refined DDPPQ. The refined DDPPQ respondents rated agreement on a
seven-point Likert scale from strongly disagree (score of 1) to strongly agree (score of 7).
Before performing the analyses, each of the negatively worded items in the self-esteem subscale
were reverse coded. The five subscales in the refined 20-item DDPPQ were combined to form an
overall therapeutic commitment score ranging from 20 to 140. Higher mean Likert scores
reflected more positive attitudes towards the concept (role adequacy, legitimacy, support,
satisfaction, and self-esteem) and were associated with higher overall therapeutic commitment in
relation to caring for individuals with OUD.
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NP Attitudes on Buprenorphine Adoption and Prescribing. Pharmacology researchers
Huhn and Dunn (2017) administered a short online survey measuring US physician attitudes
towards the adoption and prescribing of buprenorphine for OUD. The project leader adapted the
questions contained in Huhn and Dunn's (2017) survey by replacing the word ‘physician’ with
‘nurse practitioner.’ Specific components of Huhn and Dunn’s (2017) study integrated into the
finalized survey included 1) reasons that Maine NPs do not receive the buprenorphine waiver; 2)
reasons that buprenorphine waivered NPs in Maine do not prescribe to capacity; and 3) resources
that might encourage more NPs in Maine to obtain the buprenorphine waiver and accept more
patients with OUD.
NP Demographics. Current research advocates for placing demographic data at the end
of surveys because they are often off-topic, less interesting and substantive, and potentially
sensitive (Dillman, Smith, & Christian, 2014). Therefore, demographic questions were placed at
the end of the survey. Since the survey was designed to be brief to encourage completion,
detailed demographic information was not collected. Respondents were only asked to include
their age, sex, highest level of education, types of NP certification(s), waiver status, clinical
context for patient care (e.g., primary care, inpatient, emergency, psychiatric/mental health
specialty care, other), and practice setting (e.g., urban, suburban, or rural).
Survey Methods
Participants received a personalized letter of invitation via email (see Appendix B) with a
carefully selected subject line (e.g., “Survey for Maine NPs on the Opioid Crisis”). To maintain
the integrity of the survey, quality control questions were included at the start of the survey (e.g.,
“Are you licensed to practice as a NP in Maine?”; “Have you completed this survey before?”;
and “Will you give your best answers to each question?”). Participants then completed the 25-
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item self-report survey that was hosted through the online manager, Qualtrics. To conclude the
survey, respondents were asked whether they wished to be entered into a random drawing of a
$500 Visa gift card. If respondents answered “yes,” the respondents were asked to enter their
preferred contact information, reminding them that all included contact information would be deidentified. Five short email reminders with varying messages were sent to engage unfinished
respondents until the survey closed (see Appendix C for email reminder scripts). Figure 2
displays a timeline of survey events.
Strategies to Achieve Maximum Response Rate
A modified Dillman process for online surveys was used to achieve a maximum response
rate (Dillman, Smith, & Christian, 2014). Evidence-based strategies employed by the project
leader to achieve a maximum response rate centered on increasing benefits, decreasing costs, and
building trust among participants, in addition to the potential use of a mixed modes survey
design (Dillman, Smith, & Christian, 2014). Figure 3 represents a visual depiction of the
strategies employed by the project leader to increase benefits, decrease costs, and build trust
among participants eligible to complete the survey.
Increasing Benefits. Increasing the benefits of survey participation is one of the first
steps to achieve maximum response rates (Dillman, Smith, & Christian, 2014). To increase
benefits for participants, the project leader 1) asked for assistance from Maine NPs, conveying
the value of their contribution by participating in a survey designed to address their particular
strengths and challenges related to caring for Mainers with OUD; 2) communicated legitimate
sponsorship from several public health and nursing leaders and organizations in Maine, including
the MNPA and Penobscot Community Health Care, in addition to collegial support from
Belmont University and the University of Maine; and 3) used a monetary incentive in the form of
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a random drawing for a $500 Visa gift card for participation (Dillman, Smith, & Christian,
2014). The project leader consistently communicated the benefits of survey participation in the
letter of invitation and subsequent email reminders.
Decreasing Costs. In contrast to communicating the benefits of survey participation, the
project leader considered various strategies to decrease the costs of survey participation
(Dillman, Smith, & Christian, 2014). To decrease costs for participants, the project leader 1)
reduced the burdens of length and complexity by only asking questions necessary to perform the
analyses required to answer the research questions that motivated the survey in the first place,
which limited the survey to an approximated time of 10 minutes or less to complete; 2) made it
convenient to respond online by emailing a personalized, mobile-friendly link directly to Maine
NPs; and 3) minimized requests to obtain personal or sensitive information (Dillman, Smith, &
Christian, 2014).
Building Trust. One of the single most important issues affecting response to surveys in
the 21st century is trust (Dillman, Smith, & Christian, 2014). To build trust among participants,
the project leader 1) identified himself as the principal investigator from Belmont University and
offered an opportunity for participants to contact him directly via email; 2) emphasized
sponsorship from a well-known Maine nursing leader and the MNPA; 3) provided a token of
appreciation in advance for participation; 4) assured participant confidentiality and protection of
data; 5) appealed to the local identify of Maine in the Qualtrics survey design; and 6) designed
all communications (e.g., letter of invitation and subsequent email reminders) with
professionalism in mind.
Mixed Mode Survey Design. Although the primary mode for completion of the survey
remained online via an emailed letter of invitation to Maine NPs, the project leader designed the
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survey for the possibility of mixed-mode data collection with the intent of improving response
rates and reducing nonresponse error (Dillman, Smith, & Christian, 2014). The project leader
offered several other modes for survey completion. First, a paper version of the survey was
distributed to Maine NPs at the MNPA state conference. Similar wording and visual formats
were used across online and paper surveys. Second, to better engage the 88 waivered NPs in
Maine, the project leader faxed a one-page letter of invitation to their practice sites with a link to
the online survey. Third, the one-page letter of invitation containing the link to the online survey
was also circulated to Maine NPs through strategic engagement with trusted organizational
leaders of several prominent healthcare organizations in Maine.
Evaluation Strategies
Descriptive statistics (i.e., frequencies and means) were computed for demographic and
work characteristics, overall therapeutic commitment scores, and reasons Maine NPs might not
be waivered to prescribe buprenorphine as well as reasons for not prescribing to capacity among
waivered NPs. The project leader performed content analysis for “other” responses, manually
folding them into established categories or new categories if the response occurred two or more
times. An independent t-test was used to compare the overall therapeutic commitment scores
between NP participants with and without the buprenorphine waiver. A one-way ANOVA was
used to compare the overall therapeutic commitment scores among NP participants in urban,
suburban, and rural practice settings. Post hoc analyses in the form of a Bonferroni correction
were used to determine which of the means (regarding NP participants in particular practice
settings) were statistically significant after the one-way ANOVA was found to be statistically
significant. Alpha levels were set at the conventional p<0.05 and analyses were conducted using
IBM SPSS version 25.0.
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Results

Demographic and Work Characteristics
Overall, 322 Maine NPs accessed the survey; of which a total of 299 NP responses were
included for data analysis. Five participants were removed based on the quality control questions
(e.g., “Are you licensed to practice as a NP in the state of Maine?”; “Have you completed this
survey before?”; and “Will you provide your best answers to each question?”). An additional 18
NP participant responses were excluded for failing to complete a significant portion of the
survey. Table 2 demonstrates the demographic and work characteristics of Maine NP
participants. A majority of NP participants were female (93.6%, n=277, N=296), with an average
age of 49.1 years. Most NP participants (86.9%, n=258, N=297) reported a master’s of science in
nursing (MSN) as their highest nursing degree earned. The family nurse practitioner (FNP)
certification was the most commonly reported NP certification (64.0%; n=208, N=325), with
37.0% (n=110, N=297) of NP participants reporting an area of primary care (e.g., family practice
and adults only) as the clinical context for patient care. Nurse practitioner participants were from
urban (36.0%, n=107, N=297), suburban (25.3%, n=75), and rural (38.7%, n=115) practice
settings. Of 298 completed responses, a total of 49 (16.4%) NP participants reported having
obtained the DEA waiver to prescribe buprenorphine.
Most Likely Clinical Response to Patients Screening Positive for Active OUD
Of 298 completed Maine NP responses (both waivered and non-waivered), the most
commonly reported clinical response to patients screening positive for active OUD was referral
to outpatient treatment (35.9%, n=107), followed by counseling or brief intervention (20.1%,
n=60) (see Table 3). More than one in five (23.8%, n=71) NP participants reported that they do
not routinely screen for OUD in clinical practice. Thirty-four (11.4%) NP participants reported
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management of OUD with buprenorphine or other MATs as their most likely clinical response to
patients screening positive for active OUD.
Overall Therapeutic Commitment Scores
With a total of 299 Maine NP participants, the data showed an overall therapeutic
commitment score of 113 (SD=14.9) (possible score between 20 and 140). These positively
skewed scores correlate with higher therapeutic commitment in relation to caring for individuals
with OUD (see Table 4). On a mean Likert-format response of 1 (strongly disagree) to 7
(strongly agree), the highest DDPPQ subscale is evident in role legitimacy (M=6.51, SD=0.62).
Role legitimacy reflected the extent to which Maine NP participants viewed particular aspects of
OUD-related patient care as being their professional responsibility in clinical practice (e.g.,
performing comprehensive health histories that ask individuals about their opioid/opiate use).
Collectively, NP participants held somewhat positive views regarding their role adequacy (e.g.,
adequate knowledge of the causes and symptoms of OUD) (M=5.71, SD=0.88) and role self
esteem (e.g., confidence to deliver competent patient care to individuals with OUD in clinical
practice) (M=5.71, SD=1.02). Of the three DDPPQ subscales representing the theoretical
construct of role security, role support (e.g., professional support from colleagues to engage in
OUD-related patient care) ranked the lowest (M=5.50, SD=1.42). Of the two DDPPQ subscales
representing the theoretical construct of therapeutic commitment, role satisfaction (e.g., finding
OUD-related patient care rewarding) ranked the lowest, revealing a somewhat positive attitude
(M=5.28, SD=1.09).
Overall Therapeutic Commitment Scores and Buprenorphine Waiver Status
Overall therapeutic commitment scores were significantly higher among Maine NP
participants who held the DEA waiver to prescribe buprenorphine (M=128, SD=9.88) than their
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non-waivered NP counterparts (M=111, SD=14.1), t(91)=10.2, p<.001, d=1.26. Levine’s test
indicated unequal variances (F=5.26, p=.022), so degrees of freedom were adjusted from 296 to
91.1 (see Table 5 for independent t-test).
Overall Therapeutic Commitment Scores and Practice Setting
An analysis of variance showed that practice setting was significant F(2, 294)=4.66,
p=.010, partial eta squared=.031 (see Table 6 for a one-way ANOVA and Bonferroni correction).
Post hoc analyses using the Bonferroni correction indicated that NP participants in urban
(M=115, SD=16.7, p=.024) and rural (M=115, SD=13.1, p=.018) practice settings had
significantly higher overall therapeutic commitment scores than their NP counterparts in
suburban (M=109, SD=14.1) practice settings.
NP Participants without a Buprenorphine Waiver
Likelihood to Obtain Buprenorphine Waiver in the Next Year. Of the 249 NP
participants who identified themselves without the buprenorphine waiver, a majority (72.9%,
n=180) indicated that they were moderately unlikely (22.3%, n=55) to extremely unlikely
(50.61%, n=125) to obtain the buprenorphine waiver in the next year (see Table 7).
Alternatively, 49 (19.7%) NP participants without the buprenorphine waiver revealed that they
were moderately likely (12.05%, n=30) to extremely likely (7.63%, n=19) to obtain the
buprenorphine waiver in the next year.
Main Reasons for Not Obtaining the Waiver. Eight-two (33.1%) NP participants
without the buprenorphine waiver perceived obtaining the buprenorphine waiver as not relevant
to their current practice setting (i.e., work in subspecialty) (see Table 7). Lack of time (14.9%,
n=37) and professional support (9.27%, n=23) emerged as important reasons for not obtaining
the buprenorphine waiver. Six-percent (n=15) of NP participants reported that they were not
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educated enough about OUD as their main reason for not obtaining the buprenorphine waiver.
Nine (3.63%) NP participants reported that the training required to obtain the buprenorphine
waiver was too cumbersome or time consuming.
Resources that Might Increase Willingness to Obtain the Waiver. Nurse practitioner
participants without the buprenorphine waiver rated professional support from their practice
partners and organization (20.9%, n=72) as well as being paired with or mentored by an
experienced buprenorphine provider (18.0%, n=62) as the top two resources that might increase
their willingness to obtain the buprenorphine waiver, followed by more continuing education
courses on OUD (16.6%, n=57) (see Table 7). More than one in five responses from NP
participants (23.5%, n=81) without a buprenorphine waiver revealed that nothing would increase
their willingness to obtain the buprenorphine waiver.
NP Participants with a Buprenorphine Waiver
Percentage of Clinical Time Using Buprenorphine for OUD. Of the 49 NP
participants who identified themselves with the buprenorphine waiver, approximately one in five
(22.5%, n=11) reported they did not spend any clinical time caring for individuals with OUD
using buprenorphine (see Table 8). Twenty (40.8%) NP participants with the buprenorphine
waiver reported spending up to 25% of their clinical time caring for individuals with OUD using
buprenorphine.
Treatment Capacity and Willingness to Add More Patients to Panel. Of the 49 NP
participants with the buprenorphine waiver, four (8.16%) indicated that they were prescribing to
full treatment capacity (see Table 8). Nurse practitioner participants with the buprenorphine
waiver not treating at full capacity were then asked about their willingness to add more patients
to their buprenorphine panel (see Table 8); of 34 completed responses, approximately two-thirds
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(67.6%, n=23) revealed that they were willing to add more patients with OUD to their
buprenorphine panel.
Resources that Might Increase Treatment Capacity. Of 79 total responses, the most
commonly selected responses by NP participants with the buprenorphine waiver that might help
them add patients with OUD to their panel and reach full treatment capacity were more local
resources for people in recovery (19.0%, n=15), more potential practice partners (15.2%, n=12),
and more referral resources for alternative treatments of chronic pain (11.4%, n=9) (see Table 8).
Importantly, 8.86% of responses indicated that NP participants with the buprenorphine waiver
had no barriers to adding patients.
Discussion
The scholarly project surveyed Maine NPs primarily through email postings to the list
serve of the MNPA to assess the overall therapeutic commitment of Maine NPs in relation to
caring for individuals with OUD as well as reasons Maine NPs do not adopt and prescribe
buprenorphine for OUD. The findings of the scholarly project provide insight to these issues and
demonstrate actionable approaches that could raise NP therapeutic commitment in relation to
caring for individuals with OUD and potentially improve buprenorphine treatment access,
quality, and capacity.
Maine NP Role Security
Shaw and colleagues (1978) postulated that role security (comprised of role adequacy,
legitimacy, and support) is the key to unlocking the healthcare provider’s therapeutic
commitment to OUD in clinical practice. Collectively, Maine NPs scored highest on the role
legitimacy subscale (M=6.51, SD=0.62), reflecting certainty in their professional responsibility
to investigate a suspected OUD. Certainty over role legitimacy makes the healthcare provider
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feel secure and therefore more inclined to approach the patient with a suspected OUD. This
finding aligns with recent US legislation (U.S. Congress, 2016; 2017) legitimizing the role of
trained NPs as prescribers of buprenorphine for OUD. This finding is also supported by previous
studies showing greater NP interest and involvement in OUD-related patient care (Andrilla et al.,
2018b; Buerhaus, DesRoches, Dittus, & Donelan, 2015; Doescher, Andrilla, Skillman, Morgan,
& Kaplan, 2014).
Maine NPs reported somewhat positive attitudes towards their role adequacy (M=5.71,
SD=0.88), exhibiting a working knowledge of OUD. This includes a fundamental understanding
of the physical and psychological signs and symptoms of OUD, factors that place individuals at
risk of developing OUD, and advising patients about opioid use. This finding is consistent with
recent state and federal legislative efforts requiring mandatory continuing medical education for
prescribers of opioids. In March 2017, Maine policymakers enacted a pivotal Maine opioid law
that requires healthcare providers (physicians, NPs, PAs), as a condition of prescribing opioid
medications, to complete three hours of continuing medical education every two years (An Act
to Prevent Opiate Abuse by Strengthening the Controlled Substances Prescription Monitoring
Program of 2017, 2016).
Alternatively, Maine NPs scored lowest on the role support subscale (M=5.50, SD=1.42),
revealing somewhat positive attitudes towards their ability to find an available colleague with
whom they could discuss any personal difficulties, clarify professional responsibilities, or help
formulate the best approach to a patient presenting with active OUD. Shaw and colleagues
(1978) believed healthcare providers unfamiliar with OUD-related patient care would be more
likely to involve themselves in such care if provided with a milieu of support. Likewise,
interventions aimed at expanding the availability of professional support statewide in
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conjunction with comprehensive education is the most likely approach to increase the overall
therapeutic commitment of Maine NPs.
Maine NP Overall Therapeutic Commitment
The mean score of overall therapeutic commitment of Maine NPs as a collective group
was 113 (SD=14.9), with a possible score between 20 and 140. This project illustrated that Maine
NPs had a constructive attitude and a moderately high degree of overall therapeutic commitment
to individuals with OUD. Although there is limited research to directly compare these results,
this finding is similar to other findings in attitudinal surveys measuring therapeutic commitment
to OUD in registered nurses (RNs) in the US (Nilsen, Stone, & Burleson, 2013) and Australia
(Ford, Bammer, & Becker, 2008).
Data from the survey demonstrated that Maine NPs with the buprenorphine waiver had
significantly higher overall therapeutic commitment scores (M=128, SD=9.88) than their nonwaivered counterparts (M=111, SD=14.1) (p<.001), scoring on average 17 points higher. This
finding is plausible since NPs who obtain the DEA waiver to prescribe buprenorphine are
displaying role legitimacy by electing to obtain the buprenorphine waiver. Waivered NPs are
also required to complete 24 hours of additional training (US Congress, 2016), contributing to
enhanced role adequacy. Prominent healthcare organizations across Maine are also strengthening
infrastructural support for waivered healthcare providers by adopting innovative care models
built on strong professional support (Maine Behavioral Healthcare, n.d.). These factors solidify
role security, leading to higher therapeutic commitment, as evidenced by higher role satisfaction
and self-esteem scores among waivered Maine NPs (Shaw et al., 1978).
The survey also revealed that Maine NPs in urban (M=115, SD=16.7, p=.024) and rural
(M=115, SD=13.1, p=.018) practice settings had significantly higher overall therapeutic
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commitment scores than their NP counterparts in suburban practice settings (M=109, SD=14.1),
scoring on average six points higher. Given the size and scope of the opioid epidemic, raising the
therapeutic commitment of Maine NPs in suburban areas is warranted. However, this finding is
reassuring as Maine is largely rural and residents in rural Maine are often disproportionately
affected by the opioid epidemic, with higher opioid overdose rates (Keyes et al., 2014;
Lenardson et al., 2016). In 2015, approximately 25,000 Mainers with OUD did not receive
treatment, according to surveys from SAMHSA (2017). Highly committed NPs in all practice
settings play a critical role in closing the substantial OUD treatment gap in Maine, especially in
areas with prolonged waiting periods and long driving distances for evidence-based care
(Sigmon, 2015).
Maine NPs without the Buprenorphine Waiver: Actionable Approaches to Increase Receipt
of the Waiver
A majority (83.6%, n=249) of Maine NP respondents reported not possessing the
buprenorphine waiver and only 19.7% (n=49) revealed that they were moderately likely to
extremely likely to obtain the buprenorphine waiver in the next year. This is a crucial target for
future interventions in terms of recruitment. Non-waivered NP respondents were most likely to
perceive the buprenorphine waiver as not relevant to their current practice setting (33.1%, n=82),
citing employment in certain subspecialties such as pediatrics or women’s health as their reason
for not acquiring the waiver. It might be a misconception to some Maine NPs that the
buprenorphine waiver is not compatible with their subspecialty. For instance, the buprenorphine
waiver is especially applicable in pediatrics and women’s health subspecialties as a large
percentage of adolescents and pregnant women with OUD go without evidence-based treatment,
according to SAMHSA data (Lipari, Park-Lee, & Van Horn, 2016; Smith & Lipari, 2017).
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Additionally, Maine NPs reported lack of time (14.9%, n=37) and professional support from
practice partners and organizations (9.27%, n=23) as the main reasons for not obtaining the
buprenorphine waiver. Similarly, time constraints and lack of professional support have emerged
in previous studies as main barriers to incorporating buprenorphine into clinical practice among
physicians (Andrilla et al., 2017; Deflavio et al., 2015).
Eighty-one (23.5%) non-waivered Maine NPs reported that nothing would increase their
willingness to obtain the buprenorphine waiver. Provider stigma is often a leading factor
preventing buprenorphine adoption and accompanied by beliefs that favor abstinence-only
approaches over those that are evidence-based (Duncan et al., 2015; Fox et al., 2016; Molfenter
et al., 2015). Facilitating positive attitudes through education tailored specifically to combating
the stigma surrounding OUD treatment as well as highlighting buprenorphine’s effectiveness and
safety is needed (DeFlavio et al., 2015; Duncan et al., 2015; Molfenter et al., 2015).
Furthermore, peer and organizational support emerged as the top resource that might increase
willingness of Maine NPs to obtain the buprenorphine waiver (20.9%, n=72), followed by
mentorship with an experienced buprenorphine provider (18.0%, n=62) and more continuing
education courses (16.6%, n=57). There are existing models of care in which these resources
have been implemented to some degree of success. For instance, professional support can be
addressed with the Vermont Hub and Spoke model, which links primary care providers with
mental health specialists to provide ongoing support and guidance for patient management.
Combined with a learning collaborative (Nordstrom et al., 2016), the Vermont Hub and Spoke
model has shown significant gains in engaging healthcare providers and increasing
buprenorphine adoption (Brooklyn & Sigmon, 2017; Sigmon, 2015).
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Maine NPs with the Buprenorphine Waiver: Actionable Approaches to Reach Full
Treatment Capacity
A majority (73.5%, n=36) of waivered Maine NP respondents reported not prescribing to
full treatment capacity and 22.5% (n=11) of waivered NP respondents reported not spending any
clinical time caring for individuals with OUD using buprenorphine, indicating that
buprenorphine treatment is largely underutilized. Although differing in methodology, this finding
is similar to other studies of waivered physicians who reported not prescribing to full treatment
capacity (Huhn & Dunn, 2017; Thomas et al., 2017). Waivered NPs reported expanding social
services (i.e., peer mentoring, family supports, housing, employment, and transportation) for
individuals with OUD as the top resource that might help them reach full treatment capacity.
Recognizing the social disparities that often prevent individuals with OUD from accessing
treatment (Keyes et al., 2014; Lenardson et al., 2016), this finding supports the conclusion that
buprenorphine and other MATs alone are not going to solve the opioid crisis—a holistic,
personalized approach is warranted.
Waivered Maine NP respondents consistently rated resources under the domain of
professional support as vital to reaching full treatment capacity. Waivered NP respondents
reported more potential practice partners (buprenorphine prescribers and mental health
counselors) (15.2%, n=12) and mentorship from an experienced buprenorphine provider (10.1%,
n=8) as top resources that might help them reach full treatment capacity. Similarly, a 2019
qualitative study conducting interviews of waivered physicians found that lack of professional
support was a main barrier deterring them from getting started and maintaining buprenorphine as
a viable treatment option for OUD in their practices (Andrilla, Moore, & Patterson, 2019).
Waivered physicians without access to local mentors reported that acquiring virtual mentors
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through the Providers Clinical Support System (PCSS)—an online SAMHSA-sponsored site
(PCSSNow.org) available to all healthcare providers including NPs—was beneficial in that the
availability of a virtual mentor to answer questions and provide clinical support made the initial
incorporation of buprenorphine into practice much less challenging (Andrilla, Moore, &
Patterson, 2019).
Practice Implications
Even though primary care-based buprenorphine is associated with improved outcomes for
individuals with OUD (Kresina et al., 2015; Mattick et al., 2014; Schuckit, 2016) and deemed
compatible with various practice settings led by NPs (US Congress, 2016), this project revealed
many Maine NPs face similar workforce barriers as physicians. According to Lowis and
colleagues (2018), barriers to evidence-based practice are not usually due to a lack of
understanding of what is most scientifically supported, but rather a lack of ability on part of the
provider (Lowis, Harrison, & Wiland, 2018). Similarly, Shaw and colleagues (1978) aimed to
improve the abilities of healthcare providers by refocusing the lens on raising their therapeutic
commitment to individuals with SUDs. Given that NPs have been tapped to play a greater role in
evidence-based OUD treatment services, healthcare organizations and practice sites examining
the prospects of implementing sustainable buprenorphine services should carefully consider the
infrastructure necessary to recruit and equip NP prescribers of buprenorphine and ultimately
facilitate their long-term commitment.
Despite strong perceptions of role legitimacy, it is important for Maine NPs as a
collective group to transfer their role legitimacy (and overall therapeutic commitment) into
evidence-based action. A notable 23.8% (n=71) of Maine NPs disclosed that they did not
routinely screen for OUD. This is an important statistic as Maine is a full practice state and NPs
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are not only afforded the ability to obtain the buprenorphine waiver, but to also perform
screenings, a form of secondary prevention. Despite the high prevalence of OUDs in Maine and
nationwide, many Americans go without life-saving, evidence-based treatment—in part, because
their OUD goes undiagnosed (SAMHSA, 2017; US Office of the Surgeon General, 2016). The
SAMHSA (n.d.) and NIDA (n.d.) strongly recommend routine screenings for opioid use among
people of all ages, regardless of specialty or practice setting. The use of validated screening tools
like the Screening, Brief Intervention, and Referral to Treatment (SBIRT) (SAMHSA-endorsed
and reimbursable) contributes to earlier identification of individuals with OUD as well as
improved care and outcomes (Aldridge et al., 2017).
Strengths and Limitations
The scholarly project has several strengths and limitations. The refined DDPPQ,
informed by the theory of therapeutic commitment, has not been tested previously with NPs.
However, the refined DDPPQ is a valid and reliable tool (Watson et al., 2007) and the theory of
therapeutic commitment is highly relevant to the practice of NPs. In terms of generalizability, the
mean age and gender of the sample were consistent with current Maine NP workforce data
(Skillman et al., 2018). Since Maine NPs were allowed to decide entirely for themselves to
participate in the survey, an inherent self-selection bias might limit the generalizability of the
findings. While the response rate could not be calculated accurately (unable to determine how
many email invitations were active or reached Maine NPs), the relatively large number of
respondents (N=299) indicated Maine NP interest in the topic and recruitment strategies as well
as overall survey design (a modified Dillman approach) were effective.
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Future Directions
Since the literature has focused exclusively on physician attitudes towards buprenorphine
integration in primary care, more studies are needed to examine the attitudes of NPs regarding
their emerging role in primary care-based buprenorphine services. The theory of therapeutic
commitment not only provides an informative and practical framework to deconstruct the
attitudes of NPs regarding their emerging role in OUD care, but also to broaden the base of the
response by raising NP commitment to OUD. Researching NP-reported barriers and facilitators
might help policymakers and the APRN community at large more fully understand the
challenges of integrating buprenorphine services into primary care and guide evidence-based
interventions aimed at overcoming the barriers. Additionally, the theory of therapeutic
commitment postulates that healthcare providers with higher levels of overall therapeutic
commitment are better positioned to achieve favorable outcomes for individuals with SUDs
(Shaw et al., 1978). Future research should focus on the evaluation of patient outcomes in NP-led
primary care practices with fully integrated buprenorphine services. Future research should also
examine ways to make processes for the treatment of OUD more efficient, so primary care
practices with waivered healthcare providers can be fully utilized and ultimately increase the
number of patients with OUD being treated with buprenorphine.
Conclusion
The rising incidence of OUD across the lifespan and in all areas of healthcare requires the
collective therapeutic commitment of NPs in Maine and nationwide. The scholarly project
identified actionable approaches that could raise NP therapeutic commitment to individuals with
OUD as well as augment NP adoption and prescribing of buprenorphine for OUD. The findings
suggested that increasing the number of waivered Maine NPs without making additional
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resources available to strengthen commitment and infrastructure is unlikely to have a large
impact on buprenorphine adoption and prescribing. To leverage the role of waivered NPs under
CARA 2016 and ensure their potential contributions are not greatly diminished, policymakers
and the APRN community in Maine should consider evidence-based interventions aimed at
fostering professional support statewide in conjunction with comprehensive education.
Identifying attitudes and implementing resources that are useful in raising Maine NP
commitment to OUD are crucial to improving treatment access and ultimately turning the tide on
the opioid epidemic.
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Table 1: Professional Characteristics of the Role Secure and
Therapeutically Committed Healthcare Provider
●
●
●
●
●
●

Demonstrates warmth and empathy
Feels optimistic about his or her work and contribution to the patient
Regards the patient as a person of value and worth
An interested and concerned listener
Attempts to understand the patient’s lived experience
Gives sound professional advice by speaking the patient’s language
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Table 2: Demographic and Work Characteristics
Age (N=289) (years)
Mean (SD)
Range

49.1 (12.2)
25-75

Sex (N=296) % (n)
Female
Male
Other

93.6% (277)
6.08% (18)
0.34% (1)

Highest Nursing Degree (N=297) % (n)
Master’s of science in nursing (MSN)
Doctorate of nursing practice (DNP)
Philosophy of science in nursing or related field (PhD)
Other

86.9% (258)
5.05% (15)
2.69% (8)
5.39% (16)

a

NP Certification(s) (N=325) % (n)
Family nurse practitioner
Psychiatric mental health nurse practitioner
Adult nurse practitioner
Acute care nurse practitioner
Emergency nurse practitioner
Adult gerontology nurse practitioner
Women’s health nurse practitioner
Pediatric nurse practitioner
Neonatal nurse practitioner
Other

64.0% (208)
10.5% (34)
7.38% (24)
3.69% (12)
0.31% (1)
4.62% (15)
1.85% (6)
4.62% (15)
0.62% (2)
2.5% (8)

Buprenorphine Waiver Status (N=298) % (n)
Waivered
Not Waivered

16.4% (49)
83.6% (249)

Clinical Context for Patient Care (N=297) % (n)
Primary care (family practice)
Primary care (adults only)
Inpatient/hospital care
Psychiatric/mental health specialty care
Pediatric care
Urgent/ambulatory care
Emergency care
Cardiology
Palliative care
Women’s health
College health
Occupational health
Orthopedics
Outpatient surgery
Neurology
Pain management
Geriatric care
Urology
Diabetes care

28.3% (84)
8.75% (26)
12.5% (37)
9.76% (29)
6.40% (19)
6.40% (19)
1.01% (3)
3.03% (9)
2.36% (7)
2.02% (6)
1.68% (5)
1.68% (5)
1.68% (5)
1.68% (5)
1.35% (4)
1.01% (3)
1.01% (3)
0.67% (2)
0.67% (2)
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Otolaryngology
Other
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0.67% (2)
7.41% (22)

Practice setting (N=297) % (n)
Urban
Suburban
Rural
a

36.0% (107)
25.3% (75)
38.7% (115)

means select all that apply question resulting in sums >299

Table 3: Most Likely Clinical Response to Patients
Screening Positive for Active Opioid Use Disorder
(N=298)
Referral for outpatient treatment for opioid use disorder
I don’t routinely screen for opioid use disorder
Counseling/brief intervention
Management of opioid use disorder with buprenorphine or
other medication assisted treatment
Referral to inpatient treatment (detox) for opioid use disorder
Referrals are case dependent
Other

35.9% (107)
23.8%% (71)
20.1% (60)
11.4% (34)
4.36% (13)
3.02% (9)
1.34% (4)
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Table 4: Maine Nurse Practitioner Overall Therapeutic Commitment to
Individuals with Opioid Use Disorder
(Total N=299)
DDPPQ Subscales

Number of
Questions

Mean Score (Likert
score = 1-7)

Standard
Deviation

Role adequacy*

7

5.71

0.88

Role legitimacy*

2

6.51

0.62

Role support*

3

5.50

1.42

Role satisfaction**

4

5.28

1.09

Role self-esteem**

4

5.71

1.02

Overall Therapeutic
Commitment Score
(Total Composite
Score)

20

113
(possible score = 20140)

14.9

Note: Higher scores denote higher therapeutic commitment.
*Represents a concept within the construct of role security.
**Represents a concept within the construct of therapeutic commitment.
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Table 5: Overall Therapeutic Commitment Score
and Buprenorphine Waiver Status
Group Statistics

Overall
Therapeutic
Commitment

Waivered?

N

Mean

SD

SD Error
Mean

Yes

49

127.63

9.887

1.411

No

249

110.60

14.063

.891

Independent Samples Test
Levene’s Test for Equality of Variances

Overall
Therapeutic
Commitment

Equal
variances
assumed
Equal
variances
not
assumed

T-test for Equality
of Means

95% Confidence
Interval of the
Difference

F

Sig.

t

df

Sig. (2tailed)

Mean
Dif.

Std.
Error
Dif.

Lower

Upper

5.263

.022

8.090

296

.000

17.034

2.106

12.890

21.178

10.206

91.124

.000

17.034

1.669

13.719

20.349
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Table 6: Overall Therapeutic Commitment Scores and Practice Setting
95% Confidence Interval
for Mean
N
Urban

Mean

Std.
Deviation

Std. Error

Lower
Bound

Upper
Bound

Min

Max

107

114.84

16.667

1.611

111.65

118.04

67

140

75

108.92

14.054

1.623

105.69

112.15

69

137

Rural

115

114.98

13.090

1.221

112.56

117.40

80

140

Total

297

113.40

14.888

.864

111.70

115.10

67

140

Suburban

Table 6 (Contin.): Overall Therapeutic Commitment Scores and
Practice Setting (ANOVA)
Sum of
Squares
Between
Groups

df

Mean Square

2015.536

2

1007.768

Within
Groups

63595.784

294

216.312

Total

65611.320

296

F
4.659

Sig.
.010
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Table 6 (Contin.) Post Hoc Tests for ANOVA: Multiple Comparisons
Dependent Variable: Overall Therapeutic Commitment
Bonferroni
95% Confidence Interval
Practice Setting

Practice Setting
Comparison

Urban

Suburban

Rural

Suburban

Rural

Mean
Difference

Std. Error

Lower
Bound

Sig.

Upper
Bound

*

2.215

.024

.59

11.25

-.141

1.975

1.000

-4.90

4.62

5.921

Urban

-5.921

*

2.215

.024

-11.25

-.59

Rural

-6.063

*

2.183

.018

-11.32

-.81

.141

1.975

1.000

-4.62

4.90

*

2.183

.018

.81

11.32

Urban

Suburban

6.063

*The mean difference is significant at the 0.05 level.
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Table 7: NP Participants without a Buprenorphine Waiver
Total N=249
Identification of likelihood to obtain buprenorphine waiver in the next year,
main reasons for not obtaining the buprenorphine waiver, and resources that
might increase willingness to obtain the buprenorphine waiver.
Likelihood to obtain buprenorphine waiver in the next year (N=249) % (n)
Extremely likely
Moderately likely
Neither likely nor unlikely
Moderately unlikely
Extremely unlikely

7.63% (19)
12.05% (30)
7.23% (18)
22.3% (55)
50.6% (125)

Main reason for not obtaining buprenorphine waiver (N=248) % (n)
Perceived as not relevant to current practice setting (work in subspecialty)
Lack of time (don’t have enough time to be inundated with buprenorphine
requests)
Lack of professional support from my practice partners and organization I
work for
No OUD problem in my practice or community
Refer to practice partners or specialists in my community
Not educated enough about OUD
Training is too cumbersome or time-consuming
Concerned about diversion
Don’t believe in buprenorphine treatment
DEA waiver to prescribe buprenorphine in progress
New to practice
End of career
Lack of interest or desire
Don’t know how to get a waiver to prescribe buprenorphine
Need more integrated, holistic services paired with buprenorphine
Reimbursement concerns
Other

33.1% (82)
14.9% (37)
9.27% (23)
8.47% (21)
6.45% (16)
6.05% (15)
3.63% (9)
2.82% (7)
2.82% (7)
2.42% (6)
2.02% (5)
1.61% (4)
1.61% (4)
1.21% (3)
1.21% (3)
0.40% (1)
2.02% (5)

Resources that will increase willingness to obtain the buprenorphine
waiver (N=344)a % (n)
Nothing will increase my willingness
Professional support from practice partners and the organization I work
for
Being paired with or mentored by an experienced buprenorphine provider
More continuing education courses on OUD
Financial assistance for waiver to prescribe buprenorphine for OUD
Change in practice setting
Dedicated time from my the organization I work for to obtain the DEA
waiver to prescribe buprenorphine
DEA waiver to prescribe buprenorphine in progress
More integrated, holistic services available
Perceived community need
Other
a

means select all that apply question resulting in sums >249

23.5% (81)
20.9% (72)
18.0% (62)
16.6% (57)
9.30% (32)
6.40% (22)
1.16% (4)
0.87% (3)
0.58% (2)
0.58% (2)
1.74% (6)
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Table 8: NP Participants with a Buprenorphine Waiver
(N=49)
Identification of clinical time spent using buprenorphine, buprenorphine
treatment capacity, willingness to add more patients to buprenorphine panel,
and resources that might help reach full buprenorphine treatment capacity.
Percent of clinical time spent caring for individuals with OUD using
buprenorphine (N=49) % (n)
0%
1-25%
26-50%
51-75%
76-100%

22.5% (11)
40.8% (20)
14.3% (7)
12.2% (6)
10.2% (5)

Prescribing to full treatment capacity (N=49) % (n)
Yes
No
Other

8.16% (4)
73.5% (36)
18.4% (9)

Willing to add more patients to buprenorphine panel (N=34) % (n)
*Includes only those who are not at full treatment capacity
Yes
No

67.6% (23)
32.4% (11)

Top three resources that would most help prescribe buprenorphine to
full treatment capacity (N=79)a % (n)
More local resources for people in recovery, including peer mentoring,
family supports, housing, employment, and transportation
More potential practice partners (buprenorphine prescribers and/or
addiction counselors) serving my local community
More referral resources for alternative treatments of chronic pain
Being paired with an experienced buprenorphine provider
I do not have any barriers to adding patients
More local counseling services
Financial reimbursement for patients who are uninsured or underinsured
Access to a regional or statewide network of clinicians to share problems,
solutions, and best practices
Training and education for office staff on the opioid epidemic and
workplace policies/protocols/processes
Training and education for clinical staff on the opioid epidemic and
evidence-based approaches
More clinical time allotted for this patient population
a

means select top three answers resulting in sums >49

19.0% (15)
15.2% (12)
11.4% (9)
10.1% (8)
10.1% (8)
8.86% (7)
7.59% (6)
5.06% (4)

3.80% (3)
2.53% (2)
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Figure 1: The Theory of Therapeutic Commitment

Description of Figure 1: Role security is the key to unlocking the healthcare provider’s
therapeutic commitment to OUD in clinical practice. To be role secure, the healthcare
provider must maintain a firm grip on the key’s bow, which represents role adequacy,
legitimacy, and support. The lock, which represents the healthcare provider’s therapeutic
commitment to OUD in clinical practice, can only be opened by the key representing role
security. The healthcare provider who maintains a position of role security will unlock his or
her therapeutic commitment to OUD in clinical practice, as evidenced by role motivation,
self-esteem, and satisfaction.

Figure 2: Timeline of Survey Events
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Appendix A: Survey

SURVEY DESCRIPTION
What is the purpose of the survey?
The survey aims to identify particular strengths and challenges of Maine nurse
practitioners related to the opioid crisis, including caring for Mainers with opioid use disorder
(OUD).
Who can take the survey and how long will it take to complete?
ALL licensed NPs in Maine can take the survey. Completion of the entire survey should take
LESS than 10 minutes. You are encouraged to answer all questions.
Are my responses confidential?
Yes. All responses are confidential and anonymous and your participation is voluntary.
This survey received verification of exemption from the Belmont University Institutional Review
Board (IRB) in Nashville, Tennessee.
Is there a financial incentive to participate?
Yes. At the end of the survey, you will be asked whether you wish to be entered into a
random drawing for a $500 Visa gift card for participation. Please note: Your name will be
entered TWICE into the random drawing of the $500 Visa gift card if you answer ALL questions
in the survey.
Background on the Principal Investigator
Jordan Porter is from Machias, Maine, and obtained his Bachelor's of Science in Nursing
(BSN) at the University of New England (UNE). This survey is part of Jordan's scholarly work
in pursuit of a Doctor of Nursing Practice (DNP) degree at Belmont University. Jordan aspires to
practice as a family nurse practitioner in Maine after graduation in May 2019.
If you have any questions or concerns about this survey, please email Jordan at
jordan.porter@pop.belmont.edu.

SCHOLARLY PROJECT REPORT

65

ALL MAINE NPs
Are you a nurse practitioner licensed in the state of Maine?
❏ Yes, I'm licensed as a nurse practitioner in Maine
❏ No
Have you taken this survey before?
❏ Yes
❏ No, I haven't taken this survey before
Will you provide your best answers to each question in this survey?
❏ Yes, I'll give my best answers
❏ No
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Role adequacy subscale
Please rate the following items addressing your current professional knowledge and
skills as a NP on opioid use disorder in your practice from 1 (strongly disagree) to 7
(strongly agree).
I feel I have a working
knowledge of opioid use
disorder and other
opioid/opiate related
problems.

1

2

3

4

5

6

7

I feel I know enough about the
causes of opioid use disorder
to carry out my role in
practice.

1

2

3

4

5

6

7

I feel I know enough about the
physical symptoms of opioid
use disorder to carry out my
role in practice.

1

2

3

4

5

6

7

I feel I know enough about the
psychological symptoms of
opioid use disorder to carry
out my role in practice.

1

2

3

4

5

6

7

I feel I know enough about the
factors which put people at
risk of developing opioid use
disorder to carry out my role
in practice.

1

2

3

4

5

6

7

I feel I know how to counsel
patients with opioid use
disorder or other opioid/opiate
related problems over the
long-term.

1

2

3

4

5

6

7

I feel like I can appropriately
advise my patients about
opioids/opiates and their
effects.

1

2

3

4

5

6

7
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Role legitimacy subscale
Please rate the following items addressing your current professional responsibility as a
NP to question patients about their opioid/opiate use in your practice from 1 (strongly
disagree) to 7 (strongly agree).
I feel I have the right to ask
patients questions about their
opioid/ opiate use when
necessary.

1

2

3

4

5

6

7

I feel I have the right to ask a
patient for any information
that is relevant to their opioid/
opiate use.

1

2

3

4

5

6

7

Role support subscale
Please rate the following items addressing your current professional support as a NP
in responding to patients with active opioid use disorder or other opioid/opiate
problems in your practice from 1 (strongly disagree) to 7 (strongly agree).

If I felt the need when working
with patients who have opioid
use disorder or other
opioid/opiate problems, I
could easily find someone
with whom I could discuss any
personal difficulties that I
might encounter.

If I felt the need when working
with patients who have opioid
use disorder or other
opioid/opiate problems, I
could easily find someone
who would help me clarify my
professional responsibilities.

1

2

3

4

5

6

7

1

2

3

4

5

6

7
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If I felt the need when working
with patients who have opioid
use disorder or other
opioid/opiate problems, I
could easily find someone
who would be able to help me
formulate the best approach
to a patient presenting to my
practice with active opioid use
disorder.

1

68

2

3

4

5

6

7

Role self-esteem subscale
Please rate the following items addressing your current professional self-esteem as a
NP in responding to patients with active opioid use disorder or other opioid/opiate
problems in your practice from 1 (strongly disagree) to 7 (strongly agree).
I feel that there is little I can
do to help patients with opioid
use disorder or other
opioid/opiate related
problems.

1

2

3

4

5

6

7

All in all, I am inclined to feel I
am a failure with patients who
have opioid use disorder or
other opioid/opiate related
problems.

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

In general, I have less respect
for patients with opioid use
disorder or other opioid/opiate
related problems than for
most other patients I work
with.
I often feel uncomfortable
when working with patients
who have opioid use disorder
or other opioid/opiate related
problems.
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Role satisfaction subscale
Please rate the following items addressing your current professional satisfaction as a
NP in responding to patients with active opioid use disorder or other opioid/opiate
problems in your practice from 1 (strongly disagree) to 7 (strongly agree).
I feel I am able to work with
those who have opioid use
disorder as well as other
patient groups.

1

2

3

4

5

6

7

In general, one can get
satisfaction from working with
patients who have opioid use
disorder and other opioid/
opiate related issues.

1

2

3

4

5

6

7

In general, it is rewarding to
work with patients who have
opioid use disorder and other
opioid/
opiate related issues.

1

2

3

4

5

6

7

In general, I feel I can
understand patients with
opioid use disorder and other
opioid/
opiate related issues.

1

2

3

4

5

6

7

Which of the following represents your MOST likely clinical response to patients who
screen POSITIVE for active opioid use disorder in your current practice?
❏ Counseling/brief intervention
❏ Management of opioid use disorder with buprenorphine (Suboxone) or other medication
assisted treatment
❏ Referral for outpatient treatment for opioid use disorder
❏ Referral to inpatient treatment (detox) for opioid use disorder
❏ None of the above, I don't routinely screen for opioid use disorder
❏ Other (please specify)__________________________________________
Have you obtained the Drug Enforcement Administration (DEA) waiver to prescribe
buprenorphine (Suboxone) for opioid use disorder as a nurse practitioner in the state of
Maine?
❏ Yes
❏ No

SCHOLARLY PROJECT REPORT

70

NON-WAIVERED BUPRENORPHINE MAINE NPs
How likely are you to obtain the DEA waiver to prescribe buprenorphine (Suboxone) for
opioid use disorder as a nurse practitioner in the state of Maine within the next year?
❏ Extremely likely
❏ Moderately likely
❏ Neither likely nor unlikely
❏ Moderately unlikely
❏ Extremely unlikely
What is your MAIN reason for NOT obtaining the DEA waiver to prescribe buprenorphine
(Suboxone) at this current moment? (Please select one answer).
❏
❏
❏
❏
❏
❏
❏
❏
❏

Lack of time (don't have enough time to be inundated with buprenorphine requests)
Lack of professional support from my practice partners and organization I work for
Not educated enough about opioid use disorder
Reimbursement concerns
Concerned about diversion
Don't believe in buprenorphine treatment
Don't know how to get a waiver to prescribe buprenorphine
No opioid use disorder problem in my practice or community
Other (please specify)____________________________________________

What resource(s), if any, will INCREASE your willingness to obtain the DEA waiver to
prescribe buprenorphine (Suboxone) for opioid use disorder as a nurse practitioner in
the state of Maine? (Select all that apply).
❏ Nothing will increase my willingness
❏ Being paired with or mentored by an experience buprenorphine prescriber
❏ Professional support from practice partners and the organization I work for
❏ More continuing education courses or professional development workshops on opioid
use disorder
❏ Financial assistance for the DEA waiver to prescribe buprenorphine for OUD
❏ Other (please specify)___________________________________________
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WAIVERED BUPRENORPHINE MAINE NPs
In your current practice, what percentage of your clinical TIME is spent caring for
patients using buprenorphine (Suboxone) as treatment for active opioid use disorder?
❏ 0%
❏ 1-25%
❏ 26-50%
❏ 51-75%
❏ 76-100%
Are you prescribing buprenorphine (Suboxone) to FULL treatment capacity (i.e., the
maximum number of patients with opioid use disorder you can treat on your
buprenorphine panel)?
❏ Yes
❏ No
❏ Other (please describe)________________________________________________
Are you willing to ADD more patients with opioid use disorder to your buprenorphine
panel in the next 3 months?
❏ Yes, I'd be willing to add more patients to my buprenorphine panel
❏ No, I'm not willing to add more patients to my buprenorphine panel
What THREE resource(s) would MOST help you prescribe buprenorphine (Suboxone) for
opioid use disorder to FULL treatment capacity (i.e., the maximum number of patients
with opioid use disorder you can treat on your buprenorphine panel)? (Please select no
more than 3 answer choices).
❏ I do not have any barriers to adding patients
❏ More potential practice partners (buprenorphine prescribers and/or addiction counselors)
serving my local community
❏ Being paired with an experienced buprenorphine provider
❏ Access to a regional or statewide network of clinicians to share problems, solutions, and
best practices
❏ Training and education for clinical staff on the opioid epidemic and evidence-based
approaches
❏ Training and education for office staff on the opioid epidemic and workplace
policies/protocols
❏ Financial reimbursement for patients who are uninsured or underinsured
❏ More local counseling services
❏ More referral resources for alternative treatments of chronic pain
❏ More local resources for people in recovery, including peer mentoring, family supports,
housing, employment, and transportation
❏ Other (please describe)________________________________________________
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DEMOGRAPHICS
What is your age (in years)?_______________________________________
What is your sex?
❏ Male
❏ Female
❏ Other ___________________________________________________________
What is your highest level of education?
❏ Masters of science in nursing (MSN)
❏ Doctorate of nursing practice (DNP)
❏ Philosophy of science in nursing or a related field doctorate (PhD)
❏ Both DNP and PhD
❏ Other (please describe)_____________________________________________
What type(s) of nurse practitioner certification(s) do you currently hold? (Select all that
apply).
❏ Family Nurse Practitioner (FNP)
❏ Psychiatric Mental Health Nurse Practitioner (PMHNP)
❏ Adult Nurse Practitioner (ANP)
❏ Acute Care Nurse Practitioner (ACNP)
❏ Emergency Nurse Practitioner (ENP)
❏ Adult Gerontology Nurse Practitioner (AGNP)
❏ Women's Health Nurse Practitioner (WHNP)
❏ Pediatric Nurse Practitioner (PNP)
❏ Neonatal Nurse Practitioner (NNP)
❏ Other (please describe)____________________________________________
Which of the following BEST describes your clinical context for patient care? (Please
choose one answer).
❏ Primary care (family practice)
❏ Primary care (adults only)
❏ Pediatric care
❏ Urgent/ambulatory care
❏ Inpatient/hospital care
❏ Emergency care
❏ Psychiatric/mental health specialty care
❏ Other (please describe)____________________________________________
How would you describe your MAIN practice setting? (Please choose one answer).
❏ Urban
❏ Suburban
❏ Rural
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RANDOM DRAWING
Do you wish to be entered into a drawing to receive a $500 Visa gift card for your
participation?
Please note: If you answered ALL questions, your name will be entered TWICE into the
random drawing of a $500 Visa gift card.
❏ Definitely yes (Please enter name, phone number, and email address in the space
provided. This information will be de-identified from your responses and remain
confidential.)
Full name: _______________________________________________
Email:___________________________________________________
❏ Definitely not
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Appendix B: Initial Letter of Invitation

Thursday, October 11, 2018
Dear Maine Nurse Practitioner,
We are writing to ask for your help by participating in a short online survey that seeks to identify particular
strengths and challenges of Maine nurse practitioners related to the opioid crisis, including caring for
Mainers with opioid use disorder.
There will be a random drawing of a $500 Visa gift card for survey participation. All Maine NPs are
eligible to participate. The survey should take less than 10 minutes to complete. Your participation
is voluntary and your responses are confidential and anonymous. If you have any questions, please
reach out to Jordan and/or Kelley via the contact information below.
You can complete the online, mobile-friendly survey here:
Survey for Maine NPs on the Opioid Crisis
Or copy and paste the URL below into your internet browser:
https://belmont.az1.qualtrics.com/jfe/form/SV_d7pbQ5ylj4Uued7
Your responses are important to us. Thank you in advance for your participation on this important
matter.
Best,

Jordan S. Porter, RN

Kelley Strout, PhD, RN

DNP Candidate, Belmont University

Assistant Professor

Nashville, TN

The University of Maine, School of Nursing

Maine Nurse Practitioner Association, Member

Orono, ME

E: jordan.porter@pop.belmont.edu

E: kelley.strout@maine.edu
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Appendix C: Email Reminder Scripts

Tuesday, October 16, 2018
Dear Maine Nurse Practitioner,
A couple days ago we sent an email to you asking for your participation in a short online survey for Maine
NPs on the opioid crisis. If you have not answered the online survey yet, we’d like to urge you to do
so. Your responses are important to us.
There will be a random drawing of a $500 Visa gift card for survey participation. All Maine NPs are
eligible to participate. The survey should take less than 10 minutes to complete. Your participation
is voluntary and your responses are confidential and anonymous. If you have any questions, please
reach out to Jordan and/or Kelley via the contact information below.
Follow this link to complete the online, mobile-friendly survey here:
Survey for Maine NPs on the Opioid Crisis
Or copy and paste the URL below into your internet browser:
https://belmont.az1.qualtrics.com/jfe/form/SV_d7pbQ5ylj4Uued7
Thank you in advance for your participation in this survey for Maine NPs on the opioid crisis.
Best,

Jordan S. Porter, RN

Kelley Strout, PhD, RN

DNP Candidate, Belmont University

Assistant Professor

Nashville, TN

The University of Maine, School of Nursing

Maine Nurse Practitioner Association, Member

Orono, ME

E: jordan.porter@pop.belmont.edu

E: kelley.strout@maine.edu
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Tuesday, October 23, 2018
Dear Maine Nurse Practitioner,
Earlier this week we sent an email to you asking for your participation in a short online survey for Maine
NPs on the opioid crisis. We need your help to ensure the results are as precise as possible.
There will be a random drawing of a $500 Visa gift card for survey participation. All Maine NPs are
eligible to participate. The survey should take less than 10 minutes to complete. Your participation
is voluntary and your responses are confidential and anonymous. If you have any questions, please
reach out to Jordan and/or Kelley via the contact information below.
Follow this link to complete the online, mobile-friendly survey here:
Survey for Maine NPs on the Opioid Crisis
Or copy and paste the URL below into your internet browser:
https://belmont.az1.qualtrics.com/jfe/form/SV_d7pbQ5ylj4Uued7
Thank you in advance for your participation in this survey for Maine NPs on the opioid crisis.
Best,

Jordan S. Porter, RN

Kelley Strout, PhD, RN

DNP Candidate, Belmont University

Assistant Professor

Nashville, TN

The University of Maine, School of Nursing

Maine Nurse Practitioner Association, Member

Orono, ME

E: jordan.porter@pop.belmont.edu

E: kelley.strout@maine.edu
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Thursday, November 1, 2018
Dear Maine Nurse Practitioner,
Last week we sent an email to you asking for your participation in a short online survey for Maine NPs on
the opioid crisis. Close to 200 Maine NPs have responded. Let's keep the momentum going! We
need your help to ensure the results are as precise as possible.
There will be a random drawing of a $500 Visa gift card for survey participation. All Maine NPs are
eligible to participate. The survey should take less than 10 minutes to complete. Your participation
is voluntary and your responses are confidential and anonymous. If you have any questions, please
reach out to Jordan and/or Kelley via the contact information below.
Follow this link to complete the online, mobile-friendly survey here:
Survey for Maine NPs on the Opioid Crisis
Or copy and paste the URL below into your internet browser:
https://belmont.az1.qualtrics.com/jfe/form/SV_d7pbQ5ylj4Uued7
Thank you in advance for your participation in this survey for Maine NPs on the opioid crisis.
Best,

Jordan S. Porter, RN

Kelley Strout, PhD, RN

DNP Candidate, Belmont University

Assistant Professor

Nashville, TN

The University of Maine, School of Nursing

Maine Nurse Practitioner Association, Member

Orono, ME

E: jordan.porter@pop.belmont.edu

E: kelley.strout@maine.edu
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Thursday, November 15, 2018
Dear Maine Nurse Practitioner,
A few weeks ago we sent an email to you asking for your participation in a short online survey for Maine
NPs on the opioid crisis. Close to 250 Maine NPs have responded. Let's keep the momentum going
before the survey closes on Friday, November 30, 2018.
There will be a random drawing of a $500 Visa gift card for survey participation. All Maine NPs are
eligible to participate. The survey should take less than 10 minutes to complete. Your participation
is voluntary and your responses are confidential and anonymous. If you have any questions, please
reach out to Jordan and/or Kelley via the contact information below.
Follow this link to complete the online, mobile-friendly survey here:
Survey for Maine NPs on the Opioid Crisis
Or copy and paste the URL below into your internet browser:
https://belmont.az1.qualtrics.com/jfe/form/SV_d7pbQ5ylj4Uued7
Thank you in advance for your participation in this survey for Maine NPs on the opioid crisis. We
appreciate the work you do. Happy NP week!
Best,

Jordan S. Porter, RN

Kelley Strout, PhD, RN

DNP Candidate, Belmont University

Assistant Professor

Nashville, TN

The University of Maine, School of Nursing

Maine Nurse Practitioner Association, Member

Orono, ME

E: jordan.porter@pop.belmont.edu

E: kelley.strout@maine.edu
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Tuesday, November 27, 2018
Dear Maine Nurse Practitioner,
Recently we sent an email to you asking for your participation in a short online survey for Maine NPs on
the opioid crisis. Close to 300 Maine NPs have responded. This is the final reminder to complete the
survey if you have not already done so. The survey closes this Friday, November 30, 2018.
There will be a random drawing of a $500 Visa gift card for survey participation. All Maine NPs are
eligible to participate. The survey should take less than 10 minutes to complete. Your participation
is voluntary and your responses are confidential and anonymous. If you have any questions, please
reach out to Jordan and/or Kelley via the contact information below.
Follow this link to complete the online, mobile-friendly survey here:
Survey for Maine NPs on the Opioid Crisis
Or copy and paste the URL below into your internet browser:
https://belmont.az1.qualtrics.com/jfe/form/SV_d7pbQ5ylj4Uued7
Thank you for your work as a Maine NP and your continued efforts to improve the health outcomes of
Mainers.
Best,

Jordan S. Porter, RN

Kelley Strout, PhD, RN

DNP Candidate, Belmont University

Assistant Professor

Nashville, TN

The University of Maine, School of Nursing

Maine Nurse Practitioner Association, Member

Orono, ME

E: jordan.porter@pop.belmont.edu

E: kelley.strout@maine.edu

